Predict your next investment

Venture Capital
hopenls.com

See what CB Insights has to offer

Investments

18

Portfolio Exits

4

Funds

2

About Hopen Life Sciences Ventures

Hopen Life Science Ventures is a venture capital firm, investing in exceptional life science and healthcare opportunities.

Hopen Life Sciences Ventures Headquarter Location

171 Monore NW Suite 410

Grand Rapids, Michigan, 49503,

United States

616-325-2110

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Hopen Life Sciences Ventures News

Intervention Insights Closes $7.2M

Jul 18, 2011

Intervention Insights Closes $7.2M July 18, 2011 Grand Rapids, Mich.-based Intervention Insights has closed on $7.2 million in Series B financing. Michigan venture investor Beringea and Louisville, Ky.-based Chrysalis Ventures co-led the round, which also included funding from Hopen Life Sciences, Michigan Accelerator Fund I. The company, a healthcare information technology start-up, will use the money to expand commercialization of its platform, designed to help community oncologists develop individualized patient treatment plans. PRESS RELEASE Intervention Insights, a Grand Rapids-based healthcare information technology company which helps community oncologists develop individualized patient treatment plans, today announced the close of $7.2 million in Series B financing. The deal was co-led by Michigan venture investor Beringea and Louisville, Ky.-based Chrysalis Ventures, who were joined by Hopen Life Sciences, Michigan Accelerator Fund I and other existing investors. In conjunction with the financing, Beringea Managing Director Michael Gross and Chrysalis Managing Director Koleman Karleski have joined the company’s board of directors. The investment will enable the company to expand the commercialization of its OncInsights product platform, while furthering strategic relationships in the cancer care industry. “Our new funding positions us well in the emerging personalized oncology market and allows us to expand our service offerings to support community oncologists,” said Jerry Callahan, CEO of Intervention Insights. “We believe that serving community oncology, as opposed to reserving ‘optimal’ care to our academic cancer centers, is a critical element in improving cancer care in the U.S., where more than 80% of all U.S. cancer patients are treated.” Founded in 2009 based on a technology licensed from the Van Andel Research Institute (VARI), Intervention Insights’ flagship product, OncInsights, is based on VARI’s powerful bioinformatics platform. The OncInsights service works by matching a patient’s unique cancer profile of more than 22,000 genes and matches the cancer’s unique genomic make-up to the molecular mechanisms of action for more than 300 drugs. The end result is an easy-to-use report, electronically delivered to the oncologist to support her in making a treatment decision. This interactive report ranks molecularly targeted therapies which may target the patient’s cancer. The OncInsights service is continually refined to provide physicians with latest evidenced-based, patient specific treatment options in an effort to improve outcomes and reduce costs. “Intervention Insights is another example of innovation emerging from the state of Michigan’s investment in life science research, resulting in an industry-leading technology that is transforming the way oncologists administer care,” said Michael Gross, managing director of Beringea. “The company’s technology is part of a rapidly emerging ‘personalized’ era of medicine, which uses a patient’s unique genetic information to tailor the appropriate therapy. Beringea is eager to help Intervention Insights bring its unique technology to a broader market and contribute to Michigan’s reputation as a leader in health care.” “We strongly believe the proliferation of new healthcare technology, information and services will result in more personalized, effective care, leading to better outcomes,” said Koleman Karleski, managing director of Chrysalis Ventures. “In addition, customized treatment programs reduce unnecessary costs to the system by eliminating ineffective drugs and therapies while keeping the quality of care high. We look forward to partnering with Intervention Insights as the company expands its OncInsights service offering and establishes strategic relationships with payers and oncologists.” About Intervention Insights Intervention Insights’ mission is to improve the lives of patients afflicted with cancer through evidence-based, molecularly targeted therapeutic interventions that are applied by community physicians. Founded in 2009 as part of a new field associating drug therapies with genomic signatures of disease — pharmacogenomics— our bioinformatics platform maps the unique genomic characteristics of a cancer specimen to treatments designed to target a patient’s unique molecular tumor profile. The technology is commercially available and used by an expanding network of community oncologists. For more information, visit www.interventioninsights.com About Beringea Beringea offers advice, guidance and capital to support growing businesses. Headquartered in Farmington Hills, Mich., the firm is Michigan’s largest and most active venture and expansion-stage capital investor. With an additional office in London, Beringea has more than 70 portfolio companies in the U.S. and UK in a range of sectors, including health care and life sciences, clean technology, advanced manufacturing, media, Internet technologies and specialized consumer products. Beringea is the manager of several funds, including the InvestMichigan! Growth Capital Fund and the ProVen family of venture capital trusts. For more information, visit www.beringea.com or www.investmichiganfund.com. About Chrysalis Ventures Chrysalis Ventures manages one of Mid-America’s largest funds for early-stage and growth investments with approximately $400 million under management. Since 1993, the firm has invested in over 65 companies, primarily in the healthcare and technology sectors. With headquarters in Louisville, Kentucky, Chrysalis has offices in Cleveland, Pittsburgh, Ann Arbor and Houston. The firm seeks to partner with entrepreneurs to build enduring businesses in industries undergoing significant transformation. © 2015 Buyouts Insider / Argosy Group LLC

Hopen Life Sciences Ventures Investments

18 Investments

Hopen Life Sciences Ventures has made 18 investments. Their latest investment was in Trapelo Health as part of their Series C on November 11, 2017.

CBI Logo

Hopen Life Sciences Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/8/2017

Series C

Trapelo Health

$4.16M

No

2

5/22/2015

Series C

NeoChord

$20M

Yes

2

9/17/2014

Debt - V

Tolera Therapeutics

$0.25M

No

1

4/21/2014

Series D

Subscribe to see more

$99M

Subscribe to see more

10

4/17/2014

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/8/2017

5/22/2015

9/17/2014

4/21/2014

4/17/2014

Round

Series C

Series C

Debt - V

Series D

Series D

Company

Trapelo Health

NeoChord

Tolera Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$4.16M

$20M

$0.25M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

1

10

10

Hopen Life Sciences Ventures Portfolio Exits

4 Portfolio Exits

Hopen Life Sciences Ventures has 4 portfolio exits. Their latest portfolio exit was Trapelo Health on March 24, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/24/2021

Acquired

$99M

5

2/10/2021

Merger

Subscribe to see more

$99M

Subscribe to see more

10

7/16/2015

IPO

Subscribe to see more

$99M

Subscribe to see more

10

7/16/2015

IPO

Subscribe to see more

$99M

Subscribe to see more

0

Date

3/24/2021

2/10/2021

7/16/2015

7/16/2015

Exit

Acquired

Merger

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

10

10

0

Hopen Life Sciences Ventures Fund History

2 Fund Histories

Hopen Life Sciences Ventures has 2 funds, including Hopen Life Science Ventures Fund II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/6/2012

Hopen Life Science Ventures Fund II LP

Multi-Stage Venture Capital

Open

$40M

1

12/31/2006

Hopen Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

3/6/2012

12/31/2006

Fund

Hopen Life Science Ventures Fund II LP

Hopen Fund I

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Status

Open

Subscribe to see more

Amount

$40M

$99M

Sources

1

10

Hopen Life Sciences Ventures Team

4 Team Members

Hopen Life Sciences Ventures has 4 team members, including current Founder, Managing Partner, Jerry Callahan.

Name

Work History

Title

Status

Jerry Callahan

Founder, Managing Partner

Current

Mark P. Olesnavage

Founder, Managing Director

Current

Gerald Callahan

Managing Director

Current

Michael Fulton

Managing Director

Current

Name

Jerry Callahan

Mark P. Olesnavage

Gerald Callahan

Michael Fulton

Work History

Title

Founder, Managing Partner

Founder, Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.